Inhibitor Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
INTIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $8,839,912 | $11,951,224 |
| Prepaid expenses and other assets | 109,243 | 23,900 |
| Total current assets | 8,949,155 | 11,975,124 |
| Total assets | $8,949,155 | 11,975,124 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $33,731 | 145,161 |
| Notes payable | - | 411,000 |
| Accrued expenses and other liabilities | 631,433 | 122,621 |
| Total current liabilities | 665,164 | 678,782 |
| Deferred revenue | 3,000,000 | 3,000,000 |
| Total liabilities | 3,665,164 | 3,678,782 |
| Commitments and contingencies (Note 8) | - | - |
| Stockholders’ equity: | ||
| Series A Preferred Stock, $0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022 | - | - |
| Series B Convertible Preferred Stock, $0.0001 par value; 7,246,377 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022 | - | - |
| Undesignated Preferred Stock, $0.0001 par value; 2,253,623 shares authorized; no shares issued or outstanding at December 31, 2023 and December 31, 2022 | - | - |
| Common stock, $0.0001 par value; 500,000,000 shares authorized; 172,023,545 and 171,793,134 shares issued and outstanding at December 31, 2023 and December 31, 2022 | 17,202 | 17,179 |
| Additional paid-in capital | 54,046,845 | 54,033,084 |
| Accumulated deficit | (48,780,056) | (45,753,921) |
| Total stockholders’ equity | 5,283,991 | 8,296,342 |
| Total liabilities and stockholders’ equity | $8,949,155 | $11,975,124 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.